Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C

BACKGROUND: An estimated 170 million individuals worldwide are infected with the hepatitis C virus (HCV). Although treatment options using a combination of pegylated interferon and ribavirin (P-IFN/RBV) are available, sustained clearance of the virus is only achieved in approximately 40% of individu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaily, Dorta Guridi, Marlen, Castellanos Fernandez, Santiago, Dueñas-Carrera, Gillian, Martínez Donato, Carmen, Valenzuela Silva, Zurina, Cinza Estevez, Enrique R., Arús Soler, Liz, Alvarez-Lajonchere, Lisset, González Fabián, Sacha, Lazo del Vallín, Elena, Ferrer Bataille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681293/
https://www.ncbi.nlm.nih.gov/pubmed/29158855
http://dx.doi.org/10.1016/j.curtheres.2017.04.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681293/
https://www.ncbi.nlm.nih.gov/pubmed/29158855
http://dx.doi.org/10.1016/j.curtheres.2017.04.006

Ejemplares similares